Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova reported consolidated revenue of ₹82,250 million for FY26, up 14.4% from ₹71,921 million in FY25, driven by growth across Radiopharma, CDMO, Generics, and Proprietary Novel Drugs segments. However, profit after tax declined sharply to ₹5,393 million from ₹8,394 million (down ~36%), due to higher employee costs, increased depreciation, and finance costs. The company reported exceptional items net of ₹592 million, including a gain on sale of the Salisbury facility (₹236m), remediation expenses at Montreal CDMO (₹535m), labor code impact (₹133m), and impairment of associate investment (₹64m). The Board recommended a final dividend of 500% (₹5 per share). Auditors issued an unmodified opinion on both standalone and consolidated results.
While revenue growth was healthy, the sharp PAT decline (down ~36% YoY) and EBITDA margin compression are concerns. The dividend declaration signals management confidence, but investors should watch for margin recovery in FY27 given the Montreal remediation costs and higher operating leverage pressure.